Journal article

Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis

Nora Penzel, Linda A Antonucci, Linda T Betz, Rachele Sanfelici, Johanna Weiske, Oliver Pogarell, Paul Cumming, Boris B Quednow, Oliver Howes, Peter Falkai, Rachel Upthegrove, Alessandro Bertolino, Stefan Borgwardt, Paolo Brambilla, Rebekka Lencer, Eva Meisenzahl, Marlene Rosen, Theresa Haidl, Lana Kambeitz-Ilankovic, Stephan Ruhrmann Show all

NEUROPSYCHOPHARMACOLOGY | SPRINGERNATURE | Published : 2021

Abstract

Cannabis use during adolescence is associated with an increased risk of developing psychosis. According to a current hypothesis, this results from detrimental effects of early cannabis use on brain maturation during this vulnerable period. However, studies investigating the interaction between early cannabis use and brain structural alterations hitherto reported inconclusive findings. We investigated effects of age of cannabis initiation on psychosis using data from the multicentric Personalized Prognostic Tools for Early Psychosis Management (PRONIA) and the Cannabis Induced Psychosis (CIP) studies, yielding a total sample of 102 clinically-relevant cannabis users with recent onset psychosi..

View full abstract

Grants

Awarded by DFG


Awarded by Australian National Health & Medical Research Council (NHMRC)


Awarded by NHMRC



Funding Acknowledgements

The CIP study is a DFG-funded project (grant agreement No. KA 4413/1-1). The PRONIA study is a European Collaboration Project funded under the 7th Framework Program under grant agreement no 602152. RU reports grants from Medical Research Council, grants from the National Institute for Health Research, and personal fees from Sunovion, outside the submitted work. NK and RS received honoraria for talks presented at education meetings organized by Otsuka/Lundbeck. CP participated in advisory boards for Janssen-Cilag, AstraZeneca, Lundbeck, and Servier and received honoraria for talks presented at educational meetings organized by AstraZeneca, Janssen-Cilag, Eli Lilly, Pfizer, Lundbeck, and Shire. CP acknowledges support by an Australian National Health & Medical Research Council (NHMRC) Senior Principal Research Fellowship (ID: 1105825), a NHMRC Program Grant (ID: 1150083). All other authors report no biomedical financial interests or potential competing interests. Open Access funding enabled and organized by Projekt DEAL.